PATENT CLAIM ANALYSIS

Application Number: 16133234
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["435", "006110"]

Abstract:
The gene responsible for encoding SERT has a functional polymorphism at the 5′-regulatory promoter region, which results in two forms, long (L) and short (S). The LL-genotype is hypothesized to play a key role in the early onset of alcohol use. The present invention discloses the differences in treatment and diagnosis based on the L or short genotypes as well as on a single nucleotide polymorphism of the SERT gene, the 3′ UTR SNP rs1042173. The present invention demonstrates the efficacy of using the drug ondansetron and similar drugs for treatment based on variations in the polymorphisms of the SERT gene as well as methods for diagnosing susceptibility to abuse of alcohol and other addiction-related diseases and disorders.

Claim (Index 17):
The method of  claim 12 , wherein ondansetron is administered at least twice a day.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 97.0
- Lexical Diversity: 1.69737
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12919905', '15397076', '14266313', '13589603', '12101943']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.621611879045031
- 35 USC 102 Novelty (BERT): 0.6228222508807824
- Combined Prediction Score: 0.6217329162286062
- Mean Citation Score: 468.220068
- Max Citation Score: 640.8491
- Similarity Product: 479.9054558790625

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test